Reactive intermediates in copanlisib metabolism identified by LC-MS/MS: phase I metabolic profiling

Copanlisib (CNB; Aliqopa™) is a novel, intravenous phosphoinositide 3-kinase inhibitor used to treat various solid and hematological malignancies. CNB was recently approved by the U.S. FDA to treat adults that relapsed after two preceding systemic therapies. Using LC-MS/MS, we screened for the in vi...

Descripción completa

Detalles Bibliográficos
Autores principales: AlRabiah, Haitham, Kadi, Adnan A., Attwa, Mohamed W., Abdelhameed, Ali S., Mostafa, Gamal A. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2019
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060959/
https://www.ncbi.nlm.nih.gov/pubmed/35517257
http://dx.doi.org/10.1039/c8ra10322d

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060959/
https://www.ncbi.nlm.nih.gov/pubmed/35517257
http://dx.doi.org/10.1039/c8ra10322d

Ejemplares similares